Get the Stockscreener App
132.25
1.23%
1.61
After Hours:
132.25
Neurocrine Biosciences Inc stock is traded at $132.25, with a volume of 1.32M.
It is up +1.23% in the last 24 hours and down -1.22% over the past month.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
See More
Previous Close:
$130.64
Open:
$129.12
24h Volume:
1.32M
Relative Volume:
1.19
Market Cap:
$13.27B
Revenue:
$2.68B
Net Income/Loss:
$428.00M
P/E Ratio:
31.58
EPS:
4.1873
Net Cash Flow:
$593.10M
1W Performance:
+2.81%
1M Performance:
-1.22%
6M Performance:
-4.26%
1Y Performance:
+12.54%
1-Day Range:
$129.12
$132.99
1-Week Range:
$126.59
$132.99
52-Week Range:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
132.25 | 13.11B | 2.68B | 428.00M | 593.10M | 4.1873 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.75 | 58.54B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.10 | 54.78B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.07 | 47.92B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.86 | 39.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
503.90 | 21.68B | 3.13B | 1.27B | 1.12B | 26.39 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - Yahoo Finance UK
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Primecap Management Co. CA - MarketBeat
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo
9,887 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Fox Run Management L.L.C. - MarketBeat
Does Strong Q4 Results And INGREZZA Guidance Change The Bull Case For Neurocrine Biosciences (NBIX)? - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Wolfe Research - MarketBeat
Wolfe Research initiates Neurocrine stock at Outperform on drug pipeline - Investing.com Australia
Neurocrine Biosciences stock rating reaffirmed at RBC on takeout potential - Investing.com Australia
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March - The AI Journal
Neurocrine plans March fireside chats at TD Cowen and Leerink - Stock Titan
Wolfe Research initiates Neurocrine stock at Outperform on drug pipeline By Investing.com - Investing.com Canada
Neurocrine Biosciences stock rating reaffirmed at RBC on takeout potential By Investing.com - Investing.com India
Investment Review: Is Neurocrine Biosciences Inc a strong growth stockWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn
Wolfe Research Begins Coverage on Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat
Wolfe Research Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform Recommendation - Nasdaq
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern - ChartMill
A Look At Neurocrine Biosciences (NBIX) Valuation After Positive Analyst Views And 2026 Guidance - simplywall.st
Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update - Insider Monkey
Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update - Finviz
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Recent Share Price Weakness - Yahoo Finance
Vanguard Group Inc. Decreases Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Position Trimmed by Persistent Asset Partners Ltd - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Fiera Capital Corp - MarketBeat
Aberdeen Group plc Reduces Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Cut to “Strong Sell” at Zacks Research - Defense World
Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
Skandinaviska Enskilda Banken AB publ Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine (NASDAQ:NBIX) Downgrade Shifts Focus Across Nasdaq Index - Kalkine Media
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza - Yahoo Finance
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Eagle Health Investments LP - MarketBeat
New Strong Sell Stocks for February 18th - Yahoo Finance
JPMorgan Chase & Co. Has $664.02 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $176.00 at JPMorgan Chase & Co. - MarketBeat
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $140.00 by Analysts at Truist Financial - MarketBeat
Truist cuts Neurocrine Bio stock price target on higher spending By Investing.com - Investing.com Canada
M&G PLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation - ChartMill
Wall Street Zen Downgrades Neurocrine Biosciences (NASDAQ:NBIX) to Buy - MarketBeat
Volatility Watch: Is Appian Corporations ROIC above industry averageMarket Activity Report & Technical Buy Zone Confirmation - baoquankhu1.vn
Neurocrine Biosciences (NBIX) Valuation Check After Strong 2025 Results And Late Stage Pipeline Progress - simplywall.st
Why Neurocrine Biosciences Inc. (NB3) stock is a strong analyst pickQuarterly Growth Report & Safe Entry Zone Identification - mfd.ru
Technical Reactions to NBIX Trends in Macro Strategies - Stock Traders Daily
Market Rankings: Why is Neurocrine Biosciences Inc. stock going upWeekly Trend Report & Technical Pattern Based Signals - mfd.ru
Can Neurocrine Biosciences Inc. maintain its current growth rateStop Loss & AI Powered Buy and Sell Recommendations - mfd.ru
Neurocrine Biosciences (NBIX) Is Down 12.1% After Issuing 2026 INGREZZA Sales GuidanceWhat's Changed - simplywall.st
Why Neurocrine Biosciences Inc. stock remains a top recommendationJuly 2025 Fed Impact & Long-Term Safe Investment Plans - mfd.ru
A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance - Yahoo Finance
How cyclical is Neurocrine Biosciences Inc.’s revenue streamWeekly Investment Recap & Low Risk Profit Maximizing Plans - mfd.ru
UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating - marketscreener.com
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):